1-8 of 8
Noopur S. Raje
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma

Available to Purchase
Johannes M. Waldschmidt, Jake A. Kloeber, Praveen Anand, Julia Frede, Antonis Kokkalis, Valeriya Dimitrova, Sayalee Potdar, Monica S. Nair, Tushara Vijaykumar, Nam Gyu Im, Amy Guillaumet-Adkins, Nitish Chopra, Hannah Stuart, Lillian Budano, Noori Sotudeh, Guangwu Guo, Clemens Grassberger, Andrew J. Yee, Jacob P. Laubach, Paul G. Richardson, Kenneth C. Anderson, Noopur S. Raje, Birgit Knoechel, Jens G. Lohr
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6432–6444.
https://doi.org/10.1158/1078-0432.CCR-21-2040
Published: 01 December 2021
View articletitled, Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Open the PDF for Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Free
Jacob P. Laubach, Chia-Jen Liu, Noopur S. Raje, Andrew J. Yee, Philippe Armand, Robert L. Schlossman, Jacalyn Rosenblatt, Jacquelyn Hedlund, Michael Martin, Craig Reynolds, Kenneth H. Shain, Ira Zackon, Laura Stampleman, Patrick Henrick, Bradley Rivotto, Kalvis T.V. Hornburg, Henry J. Dumke, Stacey Chuma, Alexandra Savell, Damian R. Handisides, Stew Kroll, Kenneth C. Anderson, Paul G. Richardson, Irene M. Ghobrial
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 478–486.
https://doi.org/10.1158/1078-0432.CCR-18-1325
Published: 15 January 2019
View articletitled, A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Open the PDF for A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma in another window
Journal Articles

Role of the RANK/RANKL Pathway in Multiple Myeloma

Free
Noopur S. Raje, Sumita Bhatta, Evangelos Terpos
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (1): 12–20.
https://doi.org/10.1158/1078-0432.CCR-18-1537
Published: 03 January 2019
View articletitled, Role of the RANK/RANKL Pathway in Multiple Myeloma
Open the PDF for Role of the RANK/RANKL Pathway in Multiple Myeloma in another window
Journal Articles

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Free
Noopur S. Raje, Edward A. Faber, Jr, Paul G. Richardson, Gary Schiller, Raymond J. Hohl, Adam D. Cohen, Andres Forero, Susan Carpenter, Tuan S. Nguyen, Ilaria Conti, Christopher J. Kaiser, Damien M. Cronier, James E. Wooldridge, Kenneth C. Anderson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (23): 5688–5695.
https://doi.org/10.1158/1078-0432.CCR-16-0201
Published: 30 November 2016
View articletitled, Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Open the PDF for Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

Free
Sevim Dalva-Aydemir, Richa Bajpai, Maylyn Martinez, Kehinde U.A. Adekola, Irawati Kandela, Changyong Wei, Seema Singhal, Jennifer E. Koblinski, Noopur S. Raje, Steven T. Rosen, Mala Shanmugam
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (5): 1161–1171.
https://doi.org/10.1158/1078-0432.CCR-14-1088
Published: 01 March 2015
View articletitled, Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Open the PDF for Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin in another window
Includes: Supplementary data
Journal Articles

Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy

Free
Chirayu G. Patel, Andrew J. Yee, Tyler A. Scullen, Neeharika Nemani, Loredana Santo, Paul G. Richardson, Jacob P. Laubach, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Kenneth C. Anderson, Noopur S. Raje
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (15): 3955–3961.
https://doi.org/10.1158/1078-0432.CCR-14-0434
Published: 31 July 2014
View articletitled, Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy
Open the PDF for Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy in another window
Journal Articles

Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

Free
Melissa G. Ooi, Patrick J. Hayden, Vassiliki Kotoula, Douglas W. McMillin, Elpida Charalambous, Emily Daskalaki, Noopur S. Raje, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Leutz Buon, Martin Clynes, Peter O'Gorman, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C. Anderson, Nicholas Mitsiades
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7153–7160.
https://doi.org/10.1158/1078-0432.CCR-09-1071
Published: 30 November 2009
View articletitled, Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib
Open the PDF for Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib in another window
Includes: Supplementary data
Journal Articles

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

Free
Hiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, Robert J. Lutz, Hiroshi Yasui, Yutaka Okawa, Tanyel Kiziltepe, Sonia Vallet, Samantha Pozzi, Loredana Santo, Giulia Perrone, Yu-Tzu Tai, Diana Cirstea, Noopur S. Raje, Christoph Uherek, Benjamin Dälken, Silke Aigner, Frank Osterroth, Nikhil Munshi, Paul Richardson, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4028–4037.
https://doi.org/10.1158/1078-0432.CCR-08-2867
Published: 15 June 2009
View articletitled, The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
Open the PDF for The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo in another window
Includes: Supplementary data